Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (58)

III-01João Abrantes

A repeated time-to-event model for epileptic seizures in patients undergoing antiepileptic drug withdrawal during Video-EEG monitoring

Thursday 10:05-11:30

III-02Oliver Ackaert

Quantification of the effect of AZD5213 on sleep in subjects with Alzheimer’s disease or mild cognitive impairment using a two state Markov model

Thursday 10:05-11:30

III-03Rick Admiraal

Population pharmacokinetic modeling of Thymoglobulin in children receiving allogeneic-hematopoietic cell transplantation (HCT): towards individualized dosing to improve survival

Thursday 10:05-11:30

III-04

Differences in response to scopolamine between young and elderly healthy adults using a modelling approach: reduction in the central cholinergic system in the elderly?

Thursday 10:05-11:30

III-05Claire Ambery

Bayesian bio-comparability using small sample sizes and quantification of safety risk

Thursday 10:05-11:30

III-06Franc Andreu Solduga

Pharmacokinetic modeling of enterohepatic circulation of mycophenolic acid in renal transplant patients.

Thursday 10:05-11:30

III-07Natalia Aniceto

Population Pharmacokinetics-Pharmacogenetics of Efavirenz using Non-Linear Mixed Effects Modeling and Bayesian Estimation

Thursday 10:05-11:30

III-08Manel Aouri

Population pharmacokinetics and pharmacogenetics analysis of Rilpivirine in HIV-1 infected individuals

Thursday 10:05-11:30

III-09Eduardo Asín-Prieto

Population Pharmacokinetics of Daptomycin in Critically Ill Patients

Thursday 10:05-11:30

III-10Ioanna Athanasiadou

Hyperhydration may alter urine pharmacokinetic profile of drugs: A simulation study using budesonide as model drug

Thursday 10:05-11:30

III-11Charlotte Barker

Synthesising pragmatic and optimal design: NAPPA – a paediatric penicillin population pharmacokinetic study

Thursday 10:05-11:30

III-12Ana Bastos

Modeling and simulation of temocillin (TMO) in patients with end stage renal disease undergoing haemodialysis

Thursday 10:05-11:30

III-13Francesco Bellanti

New dosing recommendations in patients receiving deferiprone chelation therapy in the presence of renal complications

Thursday 10:05-11:30

III-14Jan Berkhout

Mechanism-based approaches to the analysis of comparative effectiveness in osteoporosis

Thursday 10:05-11:30

III-15Julie Bertrand

Population approach in high-throughput pharmacogenetics: challenging the maximum likelihood approaches and exploration of a Bayesian alternative

Thursday 10:05-11:30

III-16Andrzej Bienczak

Population Pharmacokinetic Analysis of Efavirenz in African Children using mixture modelling to describe clearance multimodality.

Thursday 10:05-11:30

III-17Sebastien Bihorel

KIWI: a collaborative platform for modeling and simulation

Thursday 10:05-11:30

III-18Roberto Bizzotto

Glucose Homeostasis Modeling: Improvement of the Insulin Kinetics Component

Thursday 10:05-11:30

III-19Irina Bondareva

Population modeling of steady-state pharmacokinetics of carbamazepine (CBZ) and its epoxide metabolite (CBZE) from therapeutic drug monitoring (TDM) data

Thursday 10:05-11:30

III-20Jens Markus Borghardt

The physiological interpretation of population pharmacokinetic modelling results for inhaled olodaterol

Thursday 10:05-11:30

III-21Dean Bottino

Operating Characteristics of Tumor Kinetic Response Assessments in Early Phase Oncology Trials

Thursday 10:05-11:30

III-22

Optimized Reduced Designs of Pharmacokinetic Clinical Trials Utilizing Target Mediated Drug Disposition Models

Thursday 10:05-11:30

III-23Karl Brendel

Population Pharmacokinetic modelling for a molecule S and its glucuronide metabolite including enterohepatic recycling

Thursday 10:05-11:30

III-24

Predicting clinical response using preclinical data: translational modelling of docetaxel-thalidomide combination treatment in metastatic, castrate-resistant, prostate cancer

Thursday 10:05-11:30

III-25Margreke Brill

Midazolam pharmacokinetics following semi-simultaneous oral and intravenous administration in morbidly obese patients before and 1 year after bariatric surgery

Thursday 10:05-11:30

III-26Claire Brillac

Population PK/PD modeling of tumor growth inhibition in tumor bearing mice: a translational strategy to predict clinical efficacy ?

Thursday 10:05-11:30

III-27René Bruno

Exposure-Response Modeling and Simulation of lucitanib Induced Dose Limiting Toxicities and Response Categories in Patients with Solid Tumors

Thursday 10:05-11:30

III-28Jantine Brussee

Modelling and simulation of the effect of L-arginine adjunctive therapy on vascular function in patients with moderately severe malaria

Thursday 10:05-11:30

III-29Elisa Calvier

Use of semi-physiological covariate model for maturation of glucuronidation to scale from adults to children

Thursday 10:05-11:30

III-30Ana Catalan-Latorre

A Mechanistic Population Pharmacokinetic Model For Taurine In Well And Undernourished Rats

Thursday 10:05-11:30

III-31Juan Pablo Cayun Pellizaris

Association between genetic, adverse events and pharmacokinetics in testicular cancer patients.

Thursday 10:05-11:30

III-32Pascal Chanu

Population pharmacokinetic/pharmacodynamic models to support dose selection of daratumumab in multiple myeloma patients

Thursday 10:05-11:30

III-33Aziz Chaouch

Population pharmacokinetics of oral voriconazole patients undergoing cataract surgery: modelling concentrations in plasma and in the aqueous humour

Thursday 10:05-11:30

III-34Chayan Acharya

A diagnostic tool for population models using non-compartmental analysis: nca_ppc functionality for R

Thursday 10:05-11:30

III-35Chunli Chen

Population pharmacokinetic-pharmacodynamic modelling of rifampicin treatment response in a tuberculosis acute mouse model

Thursday 10:05-11:30

III-36Manoranjenni Chetty

Exploring fixed dose versus body weight based dosing for monoclonal antibodies using physiologically based pharmacokinetic modelling.

Thursday 10:05-11:30

III-37

Population PKPD modeling of moxifloxacin effect on QT interval prolongation from baseline in Korean and Japanese healthy male and female subjects

Thursday 10:05-11:30

III-39Eirini Christodoulou

Pharmacokinetics of silibinin in mice tissues and serum after peros and intravenous administration as a HP-ß-CD lyophilized product

Thursday 10:05-11:30

III-40Jae Yong Chung

Ethnic difference of ADAS-Cog Placebo Response in Patients with Alzheimer’s Disease

Thursday 10:05-11:30

III-41

A simulation study to assess the impact of time to growth estimation shrinkage on overall survival association

Thursday 10:05-11:30

III-42Oskar Clewe

A bronchoalveolar lavage study design framework for characterization of the rate and extent of pulmonary distribution

Thursday 10:05-11:30

III-43Pieter Colin

A model-based analysis of IPEC dosing of paclitaxel in rats.

Thursday 10:05-11:30

III-44Teresa Collins

Performance of composite and serial study designs for estimation of toxicokinetic parameters.

Thursday 10:05-11:30

III-45Emmanuelle Comets

Population pharmacokinetics of mycophenolate acid and its metabolite in liver transplant patients

Thursday 10:05-11:30

III-46Ana Margarita Contreras Sandoval

PK/PD modeling of new immunotherapeutic agents in cancer

Thursday 10:05-11:30

III-47Paola Coppola

Pharmacokinetic assessment of prulifloxacin in patients with renal impairment using population pharmacokinetics modelling and simulations

Thursday 10:05-11:30

III-48Damien Cronier

A semi-mechanistic PK/PD model of vemurafenib resistance and its rescue by LY2835219, a cyclin-dependent kinase 4/6 inhibitor, in mice bearing human melanoma xenograft tumours

Thursday 10:05-11:30

III-49Chantal Csajka

Population Pharmacokinetics of Tamoxifen and three of its metabolites in Breast Cancer patients

Thursday 10:05-11:30

III-50Chenhui Deng

Within subject variability in pharmacometric count data modeling analysis: dynamic inter-occasion variability and stochastic differential equations

Thursday 10:05-11:30

III-51William Denney

What is Normal? A Meta-Analysis of Phase 1 Placebo Data

Thursday 10:05-11:30

III-52Paolo Denti

Population pharmacokinetics of cefazolin in children undergoing elective cardiac surgery

Thursday 10:05-11:30

III-53

Application of Physiologically-Based Pharmacokinetic/Pharmacodynamic Modelling in Oncology

Thursday 10:05-11:30

III-54Paul Matthias Diderichsen

Dose selection of GLPG0634, a selective JAK1 inhibitor, for rheumatoid arthritis Phase 2B studies: PK/PD modeling of pSTAT1 biomarker and DAS28 clinical response

Thursday 10:05-11:30

III-55Thomas Dorlo

Sample size estimates for a clinical trial evaluating allometric dosing of miltefosine in children with visceral leishmaniasis in East Africa

Thursday 10:05-11:30

III-56Sameer Doshi

Assessing the Influence of the Log-Transform Both Sides (LTBS) Approach on the Type 1 and Type 2 Error Rates for Clearance Estimation when using Bayesian Priors

Thursday 10:05-11:30

III-57Ignacio Hernández

Imaging procedures help compartmental analysis using nonlinear mixed effect models. Application in the field of non-clinical research.

Thursday 10:05-11:30

III-58Janna Duong

Linking mechanism-based modelling of type 2 diabetes mellitus with cardiovascular endpoints

Thursday 10:05-11:30

III-59Thomas Eissing

Target validation and lead optimization in drug development for diabetes using a physiologically-based PK/PD model of the glucose-insulin regulatory system

Thursday 10:05-11:30